Background: Nivolumab is approved in China for treatment of previously treated advanced NSCLC without EGFR/ALK alterations based on the findings of CheckMate 078 (NCT02613507), a randomized, openlabel phase 3 study in a predominantly Chinese population that demonstrated superior overall survival with nivolumab versus docetaxel. Patients were randomized 2:1 to receive nivolumab 3 mg/kg Q2W or docetaxel 75 mg/m 2 Q3W until disease progression or unacceptable toxicity. The results mirrored previous findings in the similar CheckMate 017/057 studies, which included few Asian patients. PROs in CheckMate 017/057 showed reductions in disease-related symptom burden and improvement in health-related quality of life (HRQOL). This study investigated whether similar improvements occurred in CheckMate 078. Method: Symptom burden was assessed using the Lung Cancer Symptom Scale (LCSS) average symptom burden index (ASBI). HRQOL was assessed using the LCSS 3-item global index (3-IGI) and EQ-5D-3L utility index (UI) and visual analog scale (VAS). Assessments for nivolumab and docetaxel occurred at baseline and every 4 and 3 weeks, respectively, up to week 24, and thereafter every 6 weeks for both treatments. Results: Of 504 randomized patients, 458 (91%) had evaluable PROs with baseline assessment and !1 post-baseline assessment (90.4% were Asian and 60.0% had non-squamous tumor histology). Compliance was !83% for all on-treatment PRO assessments. Ten or more patients remained on nivolumab and docetaxel until week 72 and 30, respectively. Time to first deterioration (TTD) was significantly prolonged with nivolumab vs docetaxel for all PRO measures; hazard ratios (95% confidence interval) were 0.47 (0.35À0.64) for LCSS-ASBI, 0.62 (0.47À0.83) for LCSS-3-IGI, and 0.56 (0.44À0.71) for both EQ-5D-3L VAS and UI. Deterioration rates at week 12 were significantly lower with nivolumab (LCSS, n¼313; EQ-5D-3L, n¼312) than docetaxel (LCSS, n¼137; EQ-5D-3L, n¼142) for LCSS-ASBI (31.6% vs 46.7%), EQ-5D-3L VAS (46.8% vs 58.5%), and EQ-5D-3L UI (36.5% vs 51.4%). Patients treated with nivolumab demonstrated clinically meaningful improvements for most LCSS-ASBI assessments after week 30 and all LCSS-3-IGI assessments after week 16; no clinically meaningful improvements were observed with docetaxel (descriptive). HRQOL improvements with nivolumab were observed with the EQ-5D-3L UI (weeks 20À72) and VAS (weeks 16À54), but most were not clinically meaningful. study, demonstrated significant progressionfree survival (PFS) benefit with first-line nivolumab + ipilimumab versus histology-based, platinum-doublet chemotherapy (PT-DC) in patients with advanced non-small cell lung cancer (NSCLC) and high tumor mutational burden (TMB; !10 mutations/megabase [mut/Mb]). Safety was manageable and consistent with prior reports for nivolumab + low-dose ipilimumab. Here we report efficacy and safety of nivolumab + ipilimumab versus PT-DC in the Asian subpopulation from CheckMate 227. Method: Patients with chemotherapy-naïve, histologically confirmed stage IV/recurrent NSCLC, ECOG performance status 0e1, and no known sensitizing EGFR/ALK alterations were randomized 1:1:1 to receive nivolumab + ipilimumab, nivolumab, or PT-DC (tumor programmed death ligand 1 [PD-L1] expression !1%) or 1:1:1 to nivolumab + ipilimumab, nivolumab + PT-DC, or PT-DC (tumor PD-L1 expression <1%). Nivolumab + ipilimumab was administered at nivolumab 3 mg/kg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks. Patients were treated until disease progression or unacceptable toxicity, for up to 2 years. TMB was determined from tumor tissue by FoundationOne CDx TM assay. A co-primary endpoint was PFS with nivolumab + ipilimumab versus PT-DC in patients with TMB !10 mut/ Mb. Patients enrolled from Japan, South Korea, and Taiwan were included in the Asian subpopulation. Results: Baseline characteristics of the Asian subpopulation (n¼357) were similar to the global population (N¼1739), with the exception that there were proportionally fewer female patients in the Asian subpopulation (22% versus 32%). Minimum follow-up was 11.2 months. In Asian patients with high TMB (n¼53), nivolumab + ipilimumab (n¼21) had improved efficacy versus PT-DC (n¼32) with a 66% reduction in the risk of progression/death (HR 0.34 [95% CI 0.15e0.75]). One-year PFS rates were 64% with nivolumab + ipilimumab versus 17% with PT-DC. Objective response rates were 76% with nivolumab + ipilimumab versus 22% with PT-DC. Median duration of response was not reached with nivolumab + ipilimumab versus 4.2 months with PT-DC. Grade 3e4 treatment-related adverse events (TRAEs) were reported in 40% of patients with nivolumab + ipilimumab versus 37% with PT-DC. Any grade TRAEs leading to discontinuation occurred in 22% of patients treated with nivolumab + ipilimumab versus 12% with PT-DC. Conclusion: The results of this Asian subpopulation analysis are consistent with the CheckMate 227 global population. First-line nivolumab + ipilimumab demonstrated improved efficacy compared with chemotherapy and a manageable safety profile in Asian patients with advanced NSCLC and TMB !10 mut/Mb.
study, demonstrated significant progressionfree survival (PFS) benefit with first-line nivolumab + ipilimumab versus histology-based, platinum-doublet chemotherapy (PT-DC) in patients with advanced non-small cell lung cancer (NSCLC) and high tumor mutational burden (TMB; !10 mutations/megabase [mut/Mb]). Safety was manageable and consistent with prior reports for nivolumab + low-dose ipilimumab. Here we report efficacy and safety of nivolumab + ipilimumab versus PT-DC in the Asian subpopulation from CheckMate 227. Method: Patients with chemotherapy-naïve, histologically confirmed stage IV/recurrent NSCLC, ECOG performance status 0e1, and no known sensitizing EGFR/ALK alterations were randomized 1:1:1 to receive nivolumab + ipilimumab, nivolumab, or PT-DC (tumor programmed death ligand 1 [PD-L1] expression !1%) or 1:1:1 to nivolumab + ipilimumab, nivolumab + PT-DC, or PT-DC (tumor PD-L1 expression <1%). Nivolumab + ipilimumab was administered at nivolumab 3 mg/kg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks. Patients were treated until disease progression or unacceptable toxicity, for up to 2 years. TMB was determined from tumor tissue by FoundationOne CDx TM assay. A co-primary endpoint was PFS with nivolumab + ipilimumab versus PT-DC in patients with TMB !10 mut/ Mb. Patients enrolled from Japan, South Korea, and Taiwan were included in the Asian subpopulation. Results: Baseline characteristics of the Asian subpopulation (n¼357) were similar to the global population (N¼1739), with the exception that there were proportionally fewer female patients in the Asian subpopulation (22% versus 32%). Minimum follow-up was 11.2 months. In Asian patients with high TMB (n¼53), nivolumab + ipilimumab (n¼21) had improved efficacy versus PT-DC (n¼32) with a 66% reduction in the risk of progression/death (HR 0.34 [95% CI 0.15e0.75]). One-year PFS rates were 64% with nivolumab + ipilimumab versus 17% with PT-DC. Objective response rates were 76% with nivolumab + ipilimumab versus 22% with PT-DC. Median duration of response was not reached with nivolumab + ipilimumab versus 4.2 months with PT-DC. Grade 3e4 treatment-related adverse events (TRAEs) were reported in 40% of patients with nivolumab + ipilimumab versus 37% with PT-DC. Any grade TRAEs leading to discontinuation occurred in 22% of patients treated with nivolumab + ipilimumab versus 12% with PT-DC. We have developed a unique strategy to tactically reduce on-target platelet toxicity with APG-1252, a novel dual Bcl-2/Bcl-xL inhibitor, while maintaining strong in vivo antitumor activity. APG-1252 potently inhibits tumor growth in human cancer xenograft models including SCLC models while trigged significantly less platelet killing. Method: Three clinical studies are ongoing, including two Phase I doseescalation studies in United States(NCT03080311) and Australia (ACTRN12616001597482), and a Phase I/II study in China (CTR20170976). APG-1252 dose ranging from 10 mg to 400 mg, will be administered via intravenous infusion for 30 minutes, twice weekly, once on Days 1, 4, 8, 11, 15, 18 and 22 in a 28-day-cycle, until disease progression or unacceptable toxicities. Tumor assessment per RECIST is performed every 2 cycles. The primary objective is to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), preliminary efficacy and MTD/RP2D of single-agent APG-1252 in metastatic solid tumors including SCLC. Results: As of Aug 31, 2018, 35 patients (including 17 pts with SCLC) have been treated in 6 dose level of APG-1252.The current dose level being explored is 240 mg. Here is a preliminary pool analysis of three studies. APG-1252 was well-tolerated across all dose levels tested. The MTD has not yet been reached. Most adverse events (AE) were mild or moderate in severity, no drug-related AEs leading to drug discontinuation. Only one patient experienced a drug-related serious adverse event (SAE), consisting of a decrease in platelet count was transient and recovered with 72 hours without any treatment or dose interruption. Of 10 SCLC patients who have had at least one posttreatment tumor assessment, one US patient with metastatic SCLC has confirmed partial response (PR) at a dose level of 40mg. After 6 cycles of APG-1252, the target lesion decreased by 44%. The response is durable and this patient has been receiving treatment for 16 cycles. Three patients from China at 80mg dose level had stable disease (SD) after 2 treatment cycles, one of them was confirmed SD. PK analyses indicate that AUC and Cmax increase dose proportionally over 10-160 mg range, AUC and Cmax are comparable between US and Chinese subjects at same dose level. Conclusion: APG-1252 was well-tolerated and the MTD has not been reached. Majority of AEs are Grade 1 or 2. No drug-related AE lead to treatment discontinuation. Preliminary anticancer effect had been observed in some SCLC patients.
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